BLACK DIAMOND THERAPEUTICS INC. - COMMON STOCK

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

04 Jan 2024 05:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

13 Dec 2023 04:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

06 Nov 2023 04:45:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

14 Oct 2023 09:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 09:14:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces CEO Transition

18 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

11 Sep 2023 05:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

05 Sep 2023 05:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

11 Aug 2023 04:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

29 Jun 2023 17:57:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

28 Jun 2023 13:23:52 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

27 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

13 Jun 2023 05:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

02 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 May 2023 04:30:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

18 Apr 2023 05:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

17 Apr 2023 13:01:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

09 Mar 2023 04:30:00 By Nasdaq GlobeNewswire